January 16, 2026 5:02pm

While the healthcare stocks including the C&GT sector deeply declined

Pre-open Indications: 1 Hit and 3 Miss

Long weekend, as stock and bond markets are closed on Monday for Martin Luther King Jr. Day.

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

TGIF  

No Don Quixote as I continually ask, what do all these stock sources, I-Banks and brokers do for you in providing daily information? Availability of data have made intel both complex; I see myself as a collector and my responsibility is to further identify and interpret data to bridge some gaps in an investment decision.

RMi Pre-opening: A Friday rush or brush-off? … https://www.regmedinvestors.com/articles/14271

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP! … https://www.regmedinvestors.com/articles/14249

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt? … https://www.regmedinvestors.com/articles/13812

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Friday: The Dow closed DOWN -83.11 points or -0.17%, the S&P closed DOWN -4.46 points or -0.06% while the Nasdaq closed DOWN -14.634 points or -0.06%

  • Theme of the session: National Economic Council Director Kevin Hassett will stay in his current role and might not be chosen to become the next Fed chair and Fed Governor Bowman indicated that there is room ahead for more interest rate cuts as the central bank should prioritize getting ahead of potential weakness in the labor market.

Friday’s (my) 40-company covered sector’s advance/decline line opened negative with 16 incliners, 21 decliners and 3 flats ending with a negative close of 11 incliners, 28 decliners and 1 flat

The CBOE Fear (VIX) index, Friday closed at 15.86, after Thursday’s 15.95, after Wednesday’s 16.74, Tuesday’s 15.98, Monday’s 15.09 and last Friday’s 14.48

Metrics: Friday …

  • The RUT was up +3.18 points or +0.12%,
  • The XLV was down -1.22 points or -0.78%,
  • The NBI was down -0.29 points or 0.00%;
  • The XBI was down -0.17 points or -0.17%
  • The IWM was up +0.25 or +0.09%;
  • The IBB was down -0.60 points or -0.35%,
  • The VIX was up +0.02 points or +0.13% at to 15.86

 

Q1/26 – 1 holiday, 2 neutral, 5 negative and 4 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Friday Closing UP (11 of 11)

  • BioNTech (BNTX +$2.93 after Thursday’s -$3.05 after Wednesday’s +$1.93 after Tuesday’s +$5.01 after Monday’s +$2.33),
  • Moderna (MRNA +$2.48 after Thursday’s -$1.22 after Wednesday’s +$0.98 after Tuesday’s +$5.76 after Monday’s -$0.46),
  • Vertex (VRTX +$2.44 after Thursday’s -$10.61 after Wednesday’s -$5.14 after Tuesday’s -$5.92 after Monday’s -$3.27),
  • uniQure NV (QURE +$0.84),
  • Intellia Therapeutics (NTLA +$0.61),
  • Capricor Therapeutics (CAPR +$0.31 after Thursday’s -$0.75, Wednesday $0.00, Tuesday’s +$0.28 and Monday’s +$0.67
  • Dyne Therapeutics (DYN +$0.28),
  • Precigen (PGEN +$0.27),
  • Entrada Therapeutics (TRDA +$0.18 after Thursday’s +$0.24),
  • Lenz Therapeutics (LENZ +$0.15),
  • Fate Therapeutics (FATE +$0.14),

Flat (1)

  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Thursday’s $0.0270, Wednesday’s -$0.10, Tuesday’s -$0.38 and Monday’s +$0.01)

Friday’s Closing DOWN (10 of 28):

  • IQIA Holdings (IQV -$3.61),
  • Arrowhead Pharmaceuticals (ARWR -$2.41 after Thursday’s +$0.34),
  • Vericel (VCEL -$1.17 after Thursday’s +$1.24),
  • Ultragenyx Pharmaceuticals (RARE -$1.01),
  • Ionis Pharmaceuticals (IONS -$0.88 after Thursday’s -$1.66 after Wednesday’s -$0.61 after Tuesday’s -$2.18 after Monday’s +$1.36),
  • Beam Therapeutics (BEAM -$0.83 after Thursday’s -$3.36 after Wednesday’s +$0.86 after Tuesday’s +$0.86 after Monday’s +$6.14),
  • CRISPR Therapeutics (CRSP -$0.70 after Thursday’s -$2.68 after Wednesday’s +$0.71 after Tuesday’s +$0.88 after Monday’s +$1.46),
  • Wave Life Sciences (WVE -$0.41),
  • Agenus (AGEN -$0.34),
  • Alnylam Pharmaceuticals (ALNY -$0.33 after Thursday’s -$7.53 after Wednesday’s -$3.10 after Tuesday’s -$0.95 after Monday’s -$27.38),

 

The Bottom Line: More of the … WHY

Indexes ended Friday just below the flatline and posted a losing week as traders weighed the latest comments made by President Trump related to the Fed and geopolitics.

Indexes gave up earlier gains on Friday after President Trump expressed fresh reluctance to name Kevin Hassett as the next Fed chair, fueling speculation that the Fed may not be as dovish as the market expected once Powell steps down in May.

For the week:

  • The S&P 500 is down 26.27 points, or 0.4%.
  • The Dow is down 144.74 points, or 0.3%.
  • The Nasdaq is down 155.96 points, or 0.7%.
  • The Russell 2000 is up 53.51 points, or 2%.

The Russell 2000 is on track to post a better daily move than the S&P 500 for an 11th straight session on Friday. That would mark the longest such period since a 13-day streak recorded in June 2008.

  • The Russell 2000 has climbed more than 8% in 2026.
  • That marks a turn for small-cap index, which has lagged the broader market over the last several years.

 

From My coverage list: Adverum Biotechnologies (ADVM) dropped as acquired with Dyne therapeutics (DYN) added

  • Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
  • It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
  • The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

 

For all my … <some say> … RANTINGS, I say TRUTH …

Capricor Therapeutics (CAPR) closed Friday closed up =$o.31 <look at the volume 974,340 shares trading <”someone’s” covering downslide (?) after Thursday down -$0.75 or -3.03% with 1.586 M shares traded <was as low of -$1.11> after Wednesday neutral ($0.00) < was at a low of -$0.45> post Tuesday’s +$0.28 (having opened -$0.26) after Monday closed up +$0.67 after being DOWN Friday -$1.71 or -6.69% to $23.84 after Thursday’s -$0.76 or -2.89% to $25.55 after Wednesday’s +$0.20 …

  • CAPR’s I-Banks seemed to be executing the “PUMP” to protect the offering share pricing – LOT of daily volume, institution driven … DON’T be distracted – Make a buck, CONTINUE the SELL of the overbought.
  • Right again after again and yet another again … downward!

 

RIGHT as always on this “pig” …

Harvard Apparatus RT (OTCQB: HRGN) closed flat on Friday after Thursday’s +$0.0270 with 1100 shares traded after Wednesday -$0.08 or -5.235 to $1.45 with 6,980 shares traded after Tuesday’s -$0.38 after Monday’s +$0.01 after Friday’s $0.00) after writing this a.m. 

  • As I wrote…
  • Financing on Deck: Harvard Apparatus RT (OTCQB: HRGN (Notice of Exempt Offering of Securities); who or what US institution would invest in this “entity” – broke, no patient data in 4 years, questionable management, serious unpaid bills in hundreds of thousands – partners and employees past and present.
  • An adjunct, who has the lipstick for this pig!

 

The recent profit-taking could also foreshadow some of the volatility ahead and …

  • RISK is always a factor remaining and … will boil-up under the surface until or as slight shocks rock the C&GT sector and markets!

As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

  • I would be following share pricing’s ascension on current biotech, cell and gene therapy sector upsides; so, some profiteering can be “situated” while maintaining a position, less elevated!

 

January – 3nd week: rolls on ...

  • 1/16 – Friday closed negative with 11 incliners, 28 decliners and 1 flat
  • 1/15 - Thursday closed negative with 8 incliners, 30 decliners and 2 flats
  • 1/14 – Wednesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1/13 – Tuesday closed neutral with 19 incliners, 19 decliners and 2 flats
  • 1/12 – Monday closed neutral with 19 incliners, 19 decliners and 2 flats

January 2nd week

  • 1/9 - Friday closed negative with 10 incliners, 28 decliners and 2 flats
  • 1/8 – Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 1/7 – Wednesday closed positive with 33 incliners, 4 decliners and 2 flats
  • 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

January’s 1st week:

  • 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
  • 1/1 -Thursday was a holiday, New Years Day

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Friday: BioNTech (BNTX), Moderna (MRNA) and Vertex (VRTX)
  • Thursday: Vericel (VCEL), AxoGen (AXGN) and Arrowhead Pharmaceuticals (ARWR)
  • Wednesday: Lenz Therapeutics (LENZ), BioNTech (BNTX) and Sarepta Therapeutics (SRPT)
  • Tuesday: Moderna (MRNA), BioNTech (BNTX) and Lenz Therapeutics (LENZ)
  • Monday: Beam Therapeutics (BEAM), BioNTech BNTX) and Ultragenyx Pharmaceuticals (RARE
  • Last Friday: uniQure NV (QURE), Mesoblast (MESO) and BioNTech (BNTX)
  • Last Thursday: Mesoblast (MESO), AxoGen (AXGN) and Intellia Therapeutics (NTLA)

The worst three (3) in the session: Losers

  • Friday: IQIA Holdings (IQV), Arrowhead Pharmaceuticals (ARWR) and Vericel (VCEL)
  • Thursday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Beam Therapeutics (BEAM)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Ionis Therapeutics (IONS)
  • Tuesday: Vertex (VRTX), Ionis Therapeutics (IONS) and uniQure NV (QURE)
  • Monday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Sarepta Therapeutics (SRPT)
  • Friday: Vertex (VRTX), CRISPR Therapeutics CRSP) and Vericel (VCEL)
  • Last Thursday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Moderna (MRNA)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.